Bausch & Lomb (BLCO) closed at $20.40 on October 28, 2026, up 15.8% from the previous close, on volume of 3,929,975 shares (30-day average 463,576).
Data as of October 28, 2026.
TipRanks (Thu, 29-Oct 3:01 PM ET)
BLCO Rises as Q3 Revenue Hits $1.38B and 2026 Guidance Moves Higher
Market Chameleon (Thu, 29-Oct 6:31 AM ET)
Bausch + Lomb Corporation (BLCO) Receives a Buy from Leerink Partners
TipRanks (Thu, 29-Oct 8:22 AM ET)
RBC Capital Gives a Buy Rating to Bausch + Lomb Corporation (BLCO)
TipRanks (Thu, 29-Oct 7:46 AM ET)
Business Wire (Thu, 29-Oct 7:00 AM ET)
BLCO raises full-year 2026 guidance after Q3 profit swing and broad-based segment growth
Market Chameleon (Wed, 28-Oct 7:03 AM ET)
Bausch + Lomb Lifts 2026 Outlook on Strong Third-Quarter Eye Care Growth
TipRanks (Wed, 28-Oct 7:43 AM ET)
Bausch + Lomb raises 2026 guidance as Q3 revenue grows
Seeking Alpha News (Wed, 28-Oct 7:01 AM ET)
Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance
Business Wire (Wed, 28-Oct 6:58 AM ET)
Here are the major earnings before the open Wednesday
Seeking Alpha News (Tue, 27-Oct 6:00 PM ET)
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Bausch & Lomb trades on the NYSE stock market under the symbol BLCO.
As of October 29, 2026, BLCO stock price was flat at $20.40 with 3,370,649 million shares trading.
BLCO has a beta of 0.67, meaning it tends to be less sensitive to market movements. BLCO has a correlation of 0.10 to the broad based SPY ETF.
BLCO has a market cap of $7.29 billion. This is considered a Mid Cap stock.
Last quarter Bausch & Lomb reported $1 billion in Revenue and $.34 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.12.
In the last 3 years, BLCO traded as high as $21.69 and as low as $10.45.
The top ETF exchange traded funds that BLCO belongs to (by Net Assets): MGMT, DFAX, GVLU, DFIC, GUSA.
BLCO has outperformed the market in the last year with a price return of +34.2% while the SPY ETF gained +13.1%. BLCO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +22.8% and +27.2%, respectively, while the SPY returned +4.1% and 0.0%, respectively.
BLCO support price is $20.00 and resistance is $20.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLCO shares will trade within this expected range on the day.